The United Kingdom has released updated guidance on antenatal screening and selective neonatal immunisation services for pregnant women with hepatitis B and their newborns, establishing a standardised clinical pathway to reduce mother-to-child transmission. The guidance from UK health authorities provides a comprehensive framework for identifying infected pregnancies and delivering timely immunisation to prevent vertical transmission in infants.
Key takeaways
- UK guidance establishes integrated antenatal screening and neonatal immunisation pathway for hepatitis B prevention in pregnancy
- Selective immunisation strategy targets infants born to hepatitis B-positive mothers to prevent vertical transmission
- Standardised clinical pathway aims to improve identification and management of infected pregnancies across UK health services
Hepatitis B Prevention Strategy: Antenatal to Neonatal Care Pathway
Key intervention points in the UK clinical pathway for hepatitis B management in pregnancy and neonatal period
Source: UK Department of Health & Social Care, 2026 | Georgian Medical Journal News
Antenatal Screening as Clinical Foundation
The UK guidance establishes antenatal hepatitis B screening as a mandatory component of routine pregnancy care, ensuring early identification of infected mothers. This approach aligns with recommendations from the World Health Organization (WHO), which emphasises the critical importance of maternal screening to prevent vertical transmission. Early detection allows clinicians to implement appropriate management strategies before delivery and to plan selective immunisation protocols for newborns.
The pathway specifies standardised testing protocols and timing of maternal serological assessment across UK maternity services. Pregnant women identified as hepatitis B surface antigen (HBsAg) positive receive counselling regarding transmission risk and management options for their infants, establishing informed decision-making throughout pregnancy and the perinatal period.
UK guidance establishes integrated antenatal screening and selective neonatal immunisation as a standardised pathway to prevent hepatitis B mother-to-child transmission and protect infant health.
— UK Department of Health & Social Care, 2026
Selective Neonatal Immunisation Strategy
The guidance prioritises selective immunisation for infants born to hepatitis B-positive mothers, offering protection against vertical transmission. This targeted approach ensures that newborns at highest risk receive timely vaccination during the critical neonatal period, when immunological vulnerability to hepatitis B infection is greatest.
Neonatal immunisation protocols include both hepatitis B vaccine and, in selected cases, hepatitis B immunoglobulin (HBIG), depending on maternal viral load and infectivity markers. The pathway defines specific clinical decision points for determining which neonates require passive and active immunisation, ensuring resource allocation toward highest-risk infants while maintaining universal access to protection across UK maternity units.
Follow-up serological testing is integrated into the pathway to confirm seroconversion and sustained immunity in vaccinated infants, typically conducted between 9 and 12 months of age. This monitoring element allows clinicians to identify non-responders requiring additional immunisation or investigation for potential infection.
Implementation Across UK Health Services
The standardised pathway is designed for implementation across all UK maternity and neonatal services, including National Health Service (NHS) trusts and independent providers. This consistency in clinical approach aims to eliminate geographic variation in hepatitis B screening and immunisation practices, ensuring equitable access to prevention services regardless of where pregnant women receive care.
The guidance includes training recommendations for midwives, obstetricians, neonatal nurses, and health visitors involved in antenatal screening and neonatal immunisation delivery. Clear communication pathways between maternity and neonatal services ensure continuity of care and timely implementation of immunisation protocols at delivery.
For further information on clinical updates on infectious disease prevention and health policy initiatives, consult the GMJ News archive.
What this means
Frequently asked questions
Why is antenatal screening for hepatitis B important?
Early identification of maternal hepatitis B infection allows clinicians to implement preventive interventions before delivery, including planned neonatal immunisation and monitoring. The WHO estimates that without intervention, 15–45% of hepatitis B-infected mothers transmit the virus to their newborns, establishing chronic infection in the majority of infected infants.
What is selective neonatal immunisation?
Selective immunisation targets infants born to hepatitis B-positive mothers with both hepatitis B vaccine and sometimes hepatitis B immunoglobulin, based on maternal viral load and infectivity markers. This approach ensures that highest-risk infants receive protection during the critical neonatal period when vertical transmission is most likely.
How is immunisation success confirmed?
Follow-up serological testing between 9 and 12 months of age confirms seroconversion (development of protective antibodies) in vaccinated infants. This monitoring identifies non-responders who may require additional immunisation or investigation, ensuring documented protection against hepatitis B infection.
The UK’s updated antenatal screening and neonatal immunisation pathway represents a systematic approach to hepatitis B prevention in pregnancy, integrating identification, risk stratification, and timely immunisation. As the NHS and independent maternity services implement this standardised clinical pathway, monitoring of screening uptake, immunisation coverage, and long-term infant serological outcomes will be essential to evaluate effectiveness and identify areas requiring additional support or resource allocation to ensure equitable access across all pregnant populations.
Source: Hepatitis B: antenatal screening and selective neonatal immunisation pathway, UK Department of Health & Social Care
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
